Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study

被引：0

作者：

Kazuhide Kawase

Jason L. Vittitow

Robert N. Weinreb

Makoto Araie

机构：

[1] Gifu University Hospital,Clinical Affairs

[2] Bausch + Lomb,Department of Ophthalmology and Shiley Eye Institute, Hamilton Glaucoma Center

[3] University of California San Diego,undefined

[4] Kanto Central Hospital of The Mutual Aid Association of Public School Teachers,undefined

来源：

Advances in Therapy | 2016年 / 33卷

关键词：

Intraocular pressure; Nitric oxide; Ocular hypertension; Open-angle glaucoma; Ophthalmology; Prostaglandin;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1612 / 1627

页数：15

共 50 条

[1] Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
Kawase, Kazuhide
Vittitow, Jason L.
Weinreb, Robert N.
Araie, Makoto
ADVANCES IN THERAPY, 2016, 33 (09) : 1612 - 1627
[2] Long-term Safety and Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: the JUPITER Study
Kawase, Kazuhide
Vittitow, Jason L.
Yamamoto, Tetsuya
Araie, Makoto
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
[3] Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings
Weinreb, Robert N.
Liebmann, Jeffrey M.
Martin, Keith R.
Kaufman, Paul L.
Vittitow, Jason L.
JOURNAL OF GLAUCOMA, 2018, 27 (01) : 7 - 15
[4] Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
Hoy, Sheridan M.
DRUGS, 2018, 78 (07) : 773 - 780
[5] Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
Sheridan M. Hoy
Drugs, 2018, 78 : 773 - 780
[6] Long-term Efficacy and Safety of Latanoprostene Bunod 0.024% for Intraocular Pressure Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension: APOLLO and LUNAR Studies
Vittitow, Jason L.
Liebmann, Jeffrey M.
Kaufman, Paul L.
Medeiros, Felipe A.
Martin, Keith R.
Weinreb, Robert N.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
[7] Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension The APOLLO Study
Weinreb, Robert N.
Sforzolini, Baldo Scassellati
Vittitow, Jason
Liebmann, Jeffrey
OPHTHALMOLOGY, 2016, 123 (05) : 965 - 973
[8] Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis
Lo, Tzu-Chen
Chen, Yu-Yen
Hung, Man-Chen
Chou, Pesus
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (15)
[9] Response symmetry of the eyes to latanoprostene bunod (LBN) 0.024% in open-angle glaucoma and ocular hypertension
Doustkhahvajari, Mahta
Najafi, Ahmad
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
[10] Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
Sheridan M. Hoy
Drugs, 2018, 78 : 857 - 857

← 1 2 3 4 5 →